Kevin Jain
Hematology & Oncology · Danbury, CTNPI 1790083186
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 478 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,687, 3.5 times the $1,062 reported in 2019.
Across 478 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Eisai Inc.$1K
- Novartis$1K
- Daiichi Sankyo Inc.$730
- Pfizer$683
- Astellas Pharma US Inc$611
- plus $6K from 35 others
Across 3 payments — averaging $4753.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$14K
What the payments were for
- Food & beverage$11,24399%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 50 | $1,303 |
| Eisai Inc. | 52 | $1,255 |
| Novartis | 59 | $1,134 |
| Daiichi Sankyo Inc. | 28 | $730 |
| Pfizer | 37 | $683 |
| Astellas Pharma US Inc | 21 | $611 |
| Merck | 23 | $610 |
| Sobi, Inc | 11 | $432 |
| Amgen | 18 | $386 |
| Sanofi | 15 | $374 |
| E.r. Squibb & Sons, L.L.C. | 17 | $346 |
| Seagen Inc. | 14 | $298 |
| Regeneron Healthcare Solutions, Inc. | 11 | $298 |
| AbbVie | 12 | $286 |
| Stemline Therapeutics Inc. | 12 | $284 |
| Pharmacyclics LLC, An Abbvie Company | 11 | $280 |
| Sumitomo Pharma America, Inc. | 10 | $265 |
| GSK | 10 | $250 |
| Boehringer Ingelheim | 10 | $204 |
| AstraZeneca | 10 | $180 |
| Incyte Corporation | 6 | $166 |
| Gilead | 5 | $138 |
| Bayer | 5 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Bristol Myers Squibb | 3 | $77 |
| Taiho Oncology, Inc. | 3 | $76 |
| Octapharma USA, Inc. | 2 | $65 |
| Puma Biotechnology, Inc. | 2 | $54 |
| Azurity Pharmaceuticals, Inc. | 2 | $50 |
| Rigel Pharmaceuticals, Inc. | 2 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $39 |
| Lilly USA, LLC | 1 | $32 |
| Novocure Inc. | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Morphosys, US Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $23 |
| Tesaro, Inc. | 1 | $21 |
| Exelixis Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $14 |
How this compares
$11,357 in reported general payments places this provider in the 75th percentile of 163 hematology & oncology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 22 | $159 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Danbury
- Eric MaDanbury$11K
- Robert KlossDanbury$9K
- Vincent RellaDanbury$9K
- Wenli GaoDanbury$8K
- Madhura HanmantgadDanbury$7K
- Katherine GarciaDanbury$5K
- Ravneet BajwaDanbury$5K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.